詹和道,姚江凌,崔紅旺
〔摘要〕 目的 探討連翹酯苷A對(duì)白細(xì)胞介素-1β(interleukin-1β, IL-1β)誘導(dǎo)的軟骨細(xì)胞損傷的影響及其可能的作用機(jī)制。方法 采用50 mg/L IL-1β誘導(dǎo)人關(guān)節(jié)軟骨細(xì)胞建立細(xì)胞損傷模型,記為模型組;另取未處理細(xì)胞為對(duì)照組。采用1.25、2.5、5.0 μmol/L不同濃度的連翹酯苷A處理軟骨細(xì)胞,依次記為連翹酯苷A低、中、高劑量組。ELISA法檢測(cè)炎癥因子[IL-1β、白細(xì)胞介素-6(interleukin-6, IL-6)、腫瘤壞死因子-α(tumor necrosis factor-α, TNF-α)]水平;采用流式細(xì)胞術(shù)檢測(cè)細(xì)胞凋亡率,qRT-PCR檢測(cè)circSERPINE2表達(dá)量。pcDNA、pcDNA-circSERPINE2轉(zhuǎn)染至軟骨細(xì)胞后用IL-1β處理,si-NC、si-circSERPINE2分別轉(zhuǎn)染至軟骨細(xì)胞后用連翹酯苷A與IL-1β共同處理24 h,采用ELISA法檢測(cè)IL-1β、IL-6、TNF-α的水平;流式細(xì)胞術(shù)檢測(cè)細(xì)胞凋亡率;Western blot法檢測(cè)Bax、Bcl-2蛋白表達(dá)量。結(jié)果 連翹酯苷A作用于IL-1β誘導(dǎo)的軟骨細(xì)胞后,炎癥因子(IL-1β、IL-6、TNF-α)水平、細(xì)胞凋亡率、Bax蛋白水平降低(P<0.05),Bcl-2蛋白、circSERPINE2表達(dá)水平升高(P<0.05);轉(zhuǎn)染pcDNA-circSERPINE2后炎癥因子(IL-1β、IL-6、TNF-α)表達(dá)水平及細(xì)胞凋亡率、Bax蛋白水平降低(P<0.05),Bcl-2蛋白水平升高(P<0.05);轉(zhuǎn)染si-circSERPINE2后,炎癥因子(IL-1β、IL-6、TNF-α)水平、細(xì)胞凋亡率、Bax蛋白水平升高(P<0.05),Bcl-2蛋白水平降低(P<0.05)。結(jié)論 連翹酯苷A可通過(guò)上調(diào)circSERPINE2表達(dá)而抑制細(xì)胞炎癥因子表達(dá)及細(xì)胞凋亡,從而減輕IL-1β誘導(dǎo)的關(guān)節(jié)軟骨細(xì)胞損傷。
〔關(guān)鍵詞〕 連翹酯苷A;circSERPINE2;白細(xì)胞介素-1β;人關(guān)節(jié)軟骨細(xì)胞;炎癥;細(xì)胞凋亡;Bax蛋白;Bcl-2蛋白
〔中圖分類號(hào)〕R285.5? ? ? ?〔文獻(xiàn)標(biāo)志碼〕A? ? ? ? 〔文章編號(hào)〕doi:10.3969/j.issn.1674-070X.2023.08.009
Effects of forsythoside A on IL-1β-induced chondrocyte injury
ZHAN Hedao, YAO Jiangling, CUI Hongwang*
The First Hospital of Hainan Medical College, Haikou, Hainan 570102, China
〔Abstract〕 Objective To investigate the effects of forsythoside A on IL-1β-induced chondrocyte injury and its possible mechanism of action. Methods Cell injury models of Human articular chondrocytes were established using 50 mg/L interleukin-1β (IL-1β), which were denoted as model group. The untreated chondrocytes were taken as control group. Chondrocytes treated with 1.25, 2.5 and 5.0 μmol/L forsythoside A were recorded as low-, medium- and high-dose forsythoside A groups, respectively. The levels of inflammatory factors [IL-1β, interleukin-6 (IL-6), and tumor necrosis factor-α (TNF-α)] were measured by ELISA; the apoptosis rate was determined by flow cytometry; the expression of circSERPINE2 was measured by qRT-PCR. The pcDNA and pcDNA-circSERPINE2 were separately transfected into chondrocytes which were treated with IL-1β for 24 h afterwards; the si-NC and si-circSERPINE2 were separately transfected into chondrocytes which were co-treated with forsythoside A and IL-1β for 24 h afterwards. Then, the levels of IL-1β, IL-6, and TNF-α were determined by ELISA; the apoptosis rate was measured by flow cytometry; the protein expression levels of Bax and Bcl-2 were determined by Western blot. Results After forsythoside A acting on IL-1β-induced chondrocytes, the levels of inflammatory factors (IL-1β, IL-6, and TNF-α), apoptosis rate, and Bax protein level decreased (P<0.05), while the expression levels of Bcl-2 protein and circSERPINE2 increased (P<0.05). After transfection of pcDNA-circSERPINE2, the levels of inflammatory factors (IL-1β, IL-6, and TNF-α), apoptosis rate and Bax protein level decreased (P<0.05), while Bcl-2 protein level increased (P<0.05). After transfection of si-circSERPINE2, the levels of inflammatory factors (IL-1β, IL-6, and TNF-α), apoptosis rate and Bax protein level increased (P<0.05), while Bcl-2 protein level decreased (P<0.05). Conclusion Forsythoside A could reduce IL-1β-induced chondrocyte injury by up-regulating circSERPINE2 expression and thus inhibiting the expressions of cellular inflammatory factors and apoptosis.
〔Keywords〕 forsythoside A; circSERPINE2; interleukin-1β; human articular chondrocytes; inflammation; apoptosis; Bax protein; Bcl-2 protein
骨關(guān)節(jié)炎是常見(jiàn)的一種骨關(guān)節(jié)疾病,常發(fā)生于中老年人群中,關(guān)節(jié)軟骨細(xì)胞凋亡是造成細(xì)胞損傷的重要原因[1-2]。目前,尚缺乏有效治療骨關(guān)節(jié)炎的方法。研究表明,中醫(yī)藥及其活性成分可通過(guò)抑制軟骨細(xì)胞凋亡從而達(dá)到治療骨關(guān)節(jié)炎的目的[3-4]。連翹屬于我國(guó)傳統(tǒng)中藥,被廣泛用于治療炎癥、發(fā)熱等疾病。連翹酯苷A是從連翹中分離出的主要活性成分之一,具有抗炎、抗氧化等作用,可抑制由巨噬細(xì)胞活化引起的炎癥及氧化性疾病[5]。然而,連翹酯苷A對(duì)骨關(guān)節(jié)炎的治療效果及其可能的作用機(jī)制尚未可知。失調(diào)的環(huán)狀RNA(circRNA)與骨關(guān)節(jié)炎的發(fā)展有關(guān)[6]。據(jù)報(bào)道,circRNA絲氨酸蛋白酶抑制劑家族E成員2(circSERPINE2)在骨關(guān)節(jié)炎中表達(dá)下調(diào),其過(guò)表達(dá)可減弱白細(xì)胞介素-1β(interleukin-1β, IL-1β)引起的軟骨細(xì)胞凋亡和細(xì)胞外基質(zhì)降解,是骨關(guān)節(jié)炎治療的新靶點(diǎn)[7-8]。本研究通過(guò)IL-1β誘導(dǎo)建立人關(guān)節(jié)軟骨細(xì)胞損傷模型,探討連翹酯苷A是否可通過(guò)調(diào)控circSERPINE2表達(dá)影響IL-1β誘導(dǎo)的軟骨細(xì)胞損傷。
1 材料與方法
1.1? 主要藥物、試劑及儀器
連翹酯苷A(上海詩(shī)丹德標(biāo)準(zhǔn)技術(shù)服務(wù)有限公司,批號(hào):20191201,純度≥98%);人關(guān)節(jié)軟骨細(xì)胞(上海中喬新舟生物科技有限公司,批號(hào):20191006);IL-1β(美國(guó)Sigma公司,批號(hào):20190819);DMEM培養(yǎng)液(上海碧云天公司,批號(hào):20200225);胎牛血清(美國(guó)Gibco公司,批號(hào):20200114);Trizol試劑、LipofectamineTM 3000轉(zhuǎn)染試劑(美國(guó)Invitrogen公司,批號(hào):20190907、20190903);反轉(zhuǎn)錄和熒光定量PCR試劑盒(美國(guó)Thermo Fisher公司,批號(hào):20191106);pcDNA、pcDNA-circSERPINE2、si-NC、si-circSERPINE2(上海吉瑪制藥技術(shù)有限公司,批號(hào):20190828、20190817、20200108、20200112);IL-1β、白細(xì)胞介素-6(interleukin-6, IL-6)、腫瘤壞死因子-α(tumor necrosis factor-α, TNF-α)檢測(cè)試劑盒(美國(guó)Abcam公司,批號(hào):20190206、20200324、20190907);細(xì)胞凋亡檢測(cè)試劑盒(北京索萊寶公司,批號(hào):20190706)。流式細(xì)胞儀(美國(guó)BD公司,型號(hào):FACS-Calibur);高速離心機(jī)(賽默飛世爾科技公司,型號(hào):Micro17R);PCR儀(美國(guó)ABI公司,型號(hào):HT9700)。
1.2? 方法
1.2.1? 分組及處理? 于6孔板(1×104個(gè)/孔)接種軟骨細(xì)胞,用含50 mg/L IL-1β的DMEM培養(yǎng)基培養(yǎng)24 h[9],記為模型組,未處理細(xì)胞作為對(duì)照組。用含1.25、2.5、5.0 μmol/L連翹酯苷A[10]與50 mg/L IL-1β的DMEM培養(yǎng)基培養(yǎng)24 h,依次記為連翹酯苷A低劑量組、連翹酯苷A中劑量組、連翹酯苷A高劑量組。
1.2.2? 細(xì)胞轉(zhuǎn)染? 于6孔板(1×104個(gè)/孔)接種軟骨細(xì)胞,培養(yǎng)24 h,待細(xì)胞融合至80%時(shí),參照轉(zhuǎn)染試劑操作說(shuō)明書(shū)分別將pcDNA、pcDNA-circSERPINE2、si-NC、si-circSERPINE2轉(zhuǎn)染至軟骨細(xì)胞,實(shí)驗(yàn)分為IL-1β+pcDNA組(轉(zhuǎn)染pcDNA后,用含50 mg/L IL-1β的DMEM培養(yǎng)基培養(yǎng)24 h)、IL-1β+pcDNA-circSERPINE2組(轉(zhuǎn)染pcDNA-circSERPINE2后,用含50 mg/L IL-1β的DMEM培養(yǎng)基培養(yǎng)24 h)、IL-1β+連翹酯苷A+si-NC組(轉(zhuǎn)染si-NC后,用含5.0 μmol/L連翹酯苷A與50 mg/L IL-1β的DMEM培養(yǎng)基培養(yǎng)24 h)、IL-1β+連翹酯苷A+si-circSERPINE2組(轉(zhuǎn)染si-circSERPINE2后,用含5.0 μmol/L連翹酯苷A與50 mg/L IL-1β的DMEM培養(yǎng)基培養(yǎng)24 h)。轉(zhuǎn)染后收集各組細(xì)胞行后續(xù)實(shí)驗(yàn)。
1.3? 觀察指標(biāo)
1.3.1? ELISA法檢測(cè)IL-1β、IL-6、TNF-α的水平? 將各組細(xì)胞培養(yǎng)上清液離心(350×g、10 min),取上清液,利用IL-1、IL-6、TNF-α ELISA試劑盒檢測(cè)IL-1β、IL-6、TNF-α水平。嚴(yán)格根據(jù)試劑盒說(shuō)明書(shū)進(jìn)行實(shí)驗(yàn),各組細(xì)胞離心后取上清液行后續(xù)檢測(cè),按照倍比稀釋制作標(biāo)準(zhǔn)品。將各組細(xì)胞上清液加入96孔板,分別加入樣品及標(biāo)準(zhǔn)品后洗板,加入生物素化抗體100 μL/孔,室溫下孵育60 min,洗板5次后加入辣根過(guò)氧化物酶標(biāo)記的鏈霉親和素100 μL/孔,孵育20 min后洗板5次,加入顯色劑TMB溶液100 μL/孔孵育20 min,加入終止液50 μL/孔后檢測(cè)450 nm處的吸光度(A)值,通過(guò)標(biāo)準(zhǔn)品曲線計(jì)算濃度。
1.3.2? 流式細(xì)胞術(shù)檢測(cè)細(xì)胞凋亡? 收集各組細(xì)胞并懸浮在1×結(jié)合緩沖液中,然后加入5 μL的AnnexinV-FITC溶液和10 μL PI(1 g/mL),在室溫和黑暗條件下對(duì)細(xì)胞進(jìn)行15 min染色。采用流式細(xì)胞儀檢測(cè)細(xì)胞凋亡的比例,計(jì)算細(xì)胞凋亡率。細(xì)胞凋亡率(%)=早期細(xì)胞的凋亡比例+晚期細(xì)胞的凋亡比例。
1.3.3? Western blot法檢測(cè)Bax、Bcl-2蛋白表達(dá)量
提取各組細(xì)胞中總蛋白,BCA法測(cè)定蛋白質(zhì)濃度后,將總蛋白(30 μg)通過(guò)10%十二烷基硫酸鈉-聚丙烯酰胺凝膠電泳分離后,轉(zhuǎn)至聚偏二氟乙烯膜,用5%脫脂牛奶封閉1 h后,將膜分別與Bax(1∶1 000)、Bcl-2(1∶1 000)、GAPDH一抗(1∶2 000)在4 ℃下孵育12 h,洗膜,再與辣根過(guò)氧化物酶偶聯(lián)的二抗(1∶3 000)在室溫下孵育1 h。使用增強(qiáng)的化學(xué)發(fā)光試劑顯影,曝光,Tanon600圖像分析蛋白條帶灰度值,以GAPDH為內(nèi)參計(jì)算目的蛋白的相對(duì)表達(dá)量。
1.3.4? qRT-PCR法檢測(cè)circSERPINE2的表達(dá)水平
取Trizol試劑提取各組細(xì)胞中總RNA,反轉(zhuǎn)錄為cDNA,隨后,將該cDNA與SYBR Green和特異性引物一起在qRT-PCR儀上進(jìn)行PCR擴(kuò)增。反應(yīng)系統(tǒng)(20 μL):10 μL SYBR■ Premix Ex TaqTM(2×)、0.8 μL PCR正向引物(10 μmol/L)、0.8 μL PCR反向引物(10 μmol/L)、2 μL cDNA(200 ng/μL)和6.4 μL無(wú)菌水。PCR反應(yīng)條件如下:95 ℃,30 s(預(yù)變性);95 ℃,5 s(變性),55 ℃,10 s(退火),72 ℃,15 s(延伸),共計(jì)40個(gè)循環(huán)。GAPDH為circSERPINE2的內(nèi)參基因,采用2-ΔΔCt法分析circSERPINE2相對(duì)GAPDH的表達(dá)水平。引物序列如下:circSERPINE2,正向5'-CGGGAAATCCTATCAAGTGC-3',反向5'-ATTGAAGTGGGAGCAGATGG-3';GAPDH,正向5'-GAAAGCCTGCCGGTGACTAA-3',反向5'-TTCCCGTTCTCAGCCTTGAC-3'。
1.4? 統(tǒng)計(jì)學(xué)處理
采用SPSS 21.0軟件進(jìn)行數(shù)據(jù)分析,各檢測(cè)指標(biāo)均為計(jì)量資料,以“x±s”表示。多組間比較采用單因素方差分析;組間比較采用SNK檢驗(yàn);兩組間均數(shù)比較采用t檢驗(yàn)。以P<0.05為差異具有統(tǒng)計(jì)學(xué)意義。
2 結(jié)果
2.1? 連翹酯苷A抑制IL-1β誘導(dǎo)的軟骨細(xì)胞中炎癥因子表達(dá)
與對(duì)照組比較,模型組IL-1β、IL-6、TNF-α水平升高(P<0.05);與模型組比較,連翹酯苷A低、中、高劑量組IL-1β、IL-6、TNF-α水平隨劑量升高而降低(P<0.05)。詳見(jiàn)表1。
2.2? 連翹酯苷A抑制IL-1β誘導(dǎo)的軟骨細(xì)胞凋亡
與對(duì)照組比較,模型組細(xì)胞凋亡率、Bax蛋白水平升高(P<0.05),Bcl-2蛋白水平降低(P<0.05);與模型組比較,連翹酯苷A低、中、高劑量組細(xì)胞凋亡率、Bax蛋白水平隨劑量升高而降低(P<0.05),Bcl-2蛋白水平隨劑量升高而升高(P<0.05)。詳見(jiàn)圖1、表2。
2.3? 連翹酯苷A對(duì)IL-1β誘導(dǎo)的軟骨細(xì)胞中circSERPINE2表達(dá)的影響
與對(duì)照組比較,模型組circSERPINE2表達(dá)量降低(P<0.05);與模型組比較,連翹酯苷A低、中、高劑量組circSERPINE2的表達(dá)量升高(P<0.05)。詳見(jiàn)表3。
2.4? 轉(zhuǎn)染后circSERPINE2表達(dá)比較
與pcDNA組比較,pcDNA-circSERPINE2組circSERPINE2表達(dá)量升高(P<0.05);與si-NC組比較,si-circSERPINE2組circSERPINE2表達(dá)量降低(P<0.05)。詳見(jiàn)表4。
2.5? circSERPINE2對(duì)IL-1β誘導(dǎo)的軟骨細(xì)胞中炎癥因子表達(dá)及細(xì)胞凋亡的影響
與IL-1β+pcDNA組比較,IL-1β+pcDNA-circSERPINE2組炎癥因子(IL-1β、IL-6、TNF-α)水平、細(xì)胞凋亡率、Bax蛋白水平降低(P<0.05),Bcl-2蛋白水平升高(P<0.05)。詳見(jiàn)圖2、表5。
2.6? 抑制circSERPINE2對(duì)軟骨細(xì)胞中炎癥因子表達(dá)及細(xì)胞凋亡的影響
與IL-1β+連翹酯苷A+si-NC組比較,IL-1β+連翹酯苷A+si-circSERPINE2組炎癥因子(IL-1β、IL-6、TNF-α)水平、細(xì)胞凋亡率、Bax蛋白水平升高(P<0.05),Bcl-2蛋白水平降低(P<0.05)。詳見(jiàn)表6、圖3。
3 討論
IL-1β屬于促炎細(xì)胞因子,可誘導(dǎo)軟骨細(xì)胞產(chǎn)生過(guò)度炎癥反應(yīng),甚至凋亡,促進(jìn)骨關(guān)節(jié)炎的發(fā)生和發(fā)展,被廣泛應(yīng)用于骨關(guān)節(jié)炎的病理生理學(xué)研究[11-12]。骨關(guān)節(jié)炎屬中醫(yī)學(xué)“痹病”范疇,與“痹病”中“鶴膝風(fēng)”“骨痹”“筋痹”相類似。膝關(guān)節(jié)骨性關(guān)節(jié)炎的發(fā)病與肝、脾、腎虧虛,風(fēng)、寒、濕及瘀血客于局部有關(guān),最終都導(dǎo)致局部血瘀氣滯、經(jīng)絡(luò)痹阻不通而發(fā)病。研究表明,中醫(yī)藥及其活性成分具有抗骨關(guān)節(jié)炎作用[13]。circRNA可充當(dāng)miRNA的海綿分子調(diào)節(jié)軟骨細(xì)胞增殖及凋亡,進(jìn)而參與骨關(guān)節(jié)炎發(fā)生及發(fā)展過(guò)程[14]。但circRNA是否可作為中醫(yī)藥治療骨關(guān)節(jié)炎的潛在靶點(diǎn)尚未闡明。
連翹是一種傳統(tǒng)中藥材,由于其抗氧化、抗菌和抗病毒活性,在治療發(fā)熱、炎癥和潰瘍等疾病方面發(fā)揮著重要作用[15]。連翹酯苷A是從連翹中提取的主要生物活性成分,具有多種生物學(xué)特性,尤其是抗炎特性[16]。據(jù)報(bào)道,連翹酯苷A可抑制高葡萄糖誘導(dǎo)的足細(xì)胞氧化應(yīng)激和炎癥損傷[17]。在脂多糖誘導(dǎo)的急性肺損傷中,連翹酯苷A可通過(guò)上調(diào)miR-124表達(dá),抑制TNF-α和IL-6的產(chǎn)生,在體外和體內(nèi)減輕脂多糖誘導(dǎo)的炎癥反應(yīng),進(jìn)而減輕肺損傷[18]。本研究結(jié)果顯示,IL-1β處理可促進(jìn)軟骨細(xì)胞炎癥反應(yīng)的發(fā)生和軟骨細(xì)胞凋亡的增加,與既往研究報(bào)道結(jié)果相似[19-20]。給予連翹酯苷A干預(yù)后,隨著濃度的升高,IL-1β誘導(dǎo)的軟骨細(xì)胞上清液中IL-1β、IL-6、TNF-α的水平降低,同時(shí)細(xì)胞凋亡率和Bax蛋白水平降低,Bcl-2表達(dá)水平升高,提示連翹酯苷A可抑制IL-1β誘導(dǎo)的軟骨細(xì)胞凋亡。
circSERPINE2源自SERPINE2基因,已被證實(shí)是骨關(guān)節(jié)炎中的保護(hù)性circRNA[6-7]。本研究檢測(cè)了IL-1β處理的軟骨細(xì)胞中circSERPINE2的表達(dá),發(fā)現(xiàn)circSERPINE2表達(dá)水平降低,circSERPINE2過(guò)表達(dá)可抑制IL-1β誘導(dǎo)的軟骨細(xì)胞炎癥反應(yīng)及細(xì)胞凋亡,表明circSERPINE2的減少可能與IL-1β誘導(dǎo)的軟骨細(xì)胞損傷有關(guān)。給予連翹酯苷A處理后,IL-1β誘導(dǎo)的軟骨細(xì)胞中circSERPINE2的表達(dá)量升高,提示連翹酯苷A可能通過(guò)上調(diào)circSERPINE2表達(dá)而減輕IL-1β誘導(dǎo)的軟骨細(xì)胞損傷。為進(jìn)一步驗(yàn)證circSERPINE2是否介導(dǎo)連翹酯苷A的抗骨關(guān)節(jié)炎作用,本研究在IL-1β誘導(dǎo)的軟骨細(xì)胞中敲低circSERPINE2,進(jìn)行功能回復(fù)實(shí)驗(yàn)。結(jié)果顯示,抑制circSERPINE2表達(dá)可拮抗連翹酯苷A對(duì)IL-1β誘導(dǎo)的軟骨細(xì)胞損傷的作用。
綜上所述,連翹酯苷A對(duì)IL-1β誘導(dǎo)的軟骨細(xì)胞炎癥因子表達(dá)及細(xì)胞凋亡具有抑制作用,這可能與其上調(diào)circSERPINE2表達(dá)有關(guān)。本研究表明,連翹酯苷A具有治療骨關(guān)節(jié)炎的潛在價(jià)值,但連翹酯苷A作用的circSERPINE2下游調(diào)控通路尚需進(jìn)一步探究。
參考文獻(xiàn)
[1] YU H, YAO S, ZHOU C C, et al. Morroniside attenuates apoptosis and pyroptosis of chondrocytes and ameliorates osteoarthritic development by inhibiting NF-κB signaling[J]. Journal of Ethnop?鄄
harmacology, 2021, 266: 113447.
[2] JIN J, LV X H, WANG B, et al. Limonin inhibits IL-1β-induced inflammation and catabolism in chondrocytes and ameliorates osteoarthritis by activating Nrf2[J]. Oxidative Medicine and Cellular Longevity, 2021, 2021: 7292512.
[3] 陳永健, 吳晶金, 錢富艷, 等. 益氣養(yǎng)血方抗兔膝骨關(guān)節(jié)炎模型軟骨退變的作用及機(jī)制研究[J]. 湖北中醫(yī)藥大學(xué)學(xué)報(bào), 2017, 19(4): 5-9.
[4] LI S, XIE F Q, SHI K W, et al. Gossypol ameliorates the IL-1β-induced apoptosis and inflammation in chondrocytes by suppressing the activation of TLR4/MyD88/NF-κB pathway via downregulating CX43[J]. Tissue & Cell, 2021, 73: 101621.
[5] 唐赫鵬, 車? 楠, 劉函曄, 等. 連翹酯苷A通過(guò)抑制PI3K/Akt通路并激活Nrf2/HO-1通路抑制LPS誘導(dǎo)的炎癥及氧化應(yīng)激[J]. 免疫學(xué)雜志, 2021, 37(5): 390-396.
[6] 喬凌暉, 袁? 濤, 韓? 杰, 等. 原發(fā)性膝骨關(guān)節(jié)炎患者滑膜組織中與炎癥相關(guān)circRNA的篩選和生物學(xué)功能分析[J]. 中國(guó)組織工程研究, 2022, 26(23): 3683-3690.
[7] SHEN S Y, WU Y Z, CHEN J X, et al. CircSERPINE2 protects against osteoarthritis by targeting miR-1271 and ETS-related gene[J]. Annals of the Rheumatic Diseases, 2019, 78(6): 826-836.
[8] ZHANG Q P, QIAO X M, XIA W W. CircSERPINE2 weakens IL-1β-caused apoptosis and extracellular matrix degradation of chondrocytes by regulating miR-495/TGFBR2 axis[J]. Bioscience Reports, 2020, 40(11): BSR20201601.
[9] 胡? 蔚, 毛? 強(qiáng). 刺五加苷B對(duì)IL-1β誘導(dǎo)的骨關(guān)節(jié)炎軟骨細(xì)胞凋亡的影響[J]. 中國(guó)現(xiàn)代應(yīng)用藥學(xué), 2020, 37(21): 2570-2575.
[10] 馬忠英, 張? 迪, 孫? 金, 等. 連翹酯苷A通過(guò)TLR4/NF-κB抑制PC12細(xì)胞低氧/再?gòu)?fù)氧誘導(dǎo)的炎癥反應(yīng)[J]. 安徽醫(yī)科大學(xué)學(xué)報(bào), 2021, 56(5): 730-734.
[11] JIANG J Q, CAI M S. Cardamonin inhibited IL-1β induced injury by inhibition of NLRP3 inflammasome via activating Nrf2/NQO-1 signaling pathway in chondrocyte[J]. Journal of Microbiology and Biotechnology, 2021, 31(6): 794-802.
[12] 陳浩凡, 馬燕妮, 陳健文, 等. 紅花黃色素上調(diào)miR-140-5p影響IL-1β誘導(dǎo)的骨關(guān)節(jié)炎軟骨細(xì)胞自噬、凋亡及炎性因子分泌的機(jī)制研究[J]. 中國(guó)臨床藥理學(xué)雜志, 2021, 37(24): 3350-3353.
[13] MO Z S, XU P Q, LI H Y. Stigmasterol alleviates interleukin-1beta-induced chondrocyte injury by down-regulatingsterol regulatory element binding transcription factor 2 to regulateferroptosis[J]. Bioengineered, 2021, 12(2): 9332-9340.
[14] CHEN C J, YIN P, HU S X, et al. Circular RNA-9119 protects IL-1β-treated chondrocytes from apoptosis in an osteoarthritis cell model by intercepting the microRNA-26a/PTEN axis[J]. Life Sciences, 2020, 256: 117924.
[15] 郭健敏, 富? 力, 秦麗莉, 等. 連翹苷體內(nèi)外抗病毒及解熱作用機(jī)制[J]. 中國(guó)藥理學(xué)通報(bào), 2022, 38(8): 1170-1175.
[16] 王? 蓉, 趙戈蕾, 韓? 亮. 連翹酯苷A對(duì)脂多糖介導(dǎo)的急性肺損傷小鼠肺組織的保護(hù)作用研究[J]. 中醫(yī)藥導(dǎo)報(bào), 2020, 26(16): 10-13.
[17] QUAN X H, LIU H H, YE D M, et al. Forsythoside A alleviates high glucose-induced oxidative stress and inflammation in podocytes by inactivating MAPK signaling via MMP12 inhibition[J]. Diabetes, Metabolic Syndrome and Obesity, 2021, 14: 1885-1895.
[18] LU Z B, YANG H Y, CAO H H, et al. Forsythoside A protects against lipopolysaccharide-induced acute lung injury through up-regulating microRNA-124[J]. Clinical Science, 2020, 134(19): 2549-2563.
[19] ZHANG Y W, ZHENG H H, LI B T. Circ_0110251 overexpression alleviates IL-1β-induced chondrocyte apoptosis and extracellular matrix degradation by regulating miR-3189-3p/SPRY1 axis in osteoarthritis[J]. Autoimmunity, 2022, 55(3): 168-178.
[20] ANSARI M Y, NOVAK K, HAQQI T M. ERK1/2-mediated activation of DRP1 regulates mitochondrial dynamics and apoptosis in chondrocytes[J]. Osteoarthritis and Cartilage, 2022, 30(2): 315-328.
(本文編輯? 周? 旦)
湖南中醫(yī)藥大學(xué)學(xué)報(bào)2023年8期